Top

Cancer Causes & Control

Published in:

01-12-2019 | Glioblastoma | Original Paper

Racial differences in brain cancer characteristics and survival: an analysis of SEER data

Authors: Julie A. Bytnar, Jie Lin, Craig D. Shriver, Kangmin Zhu

Published in: Cancer Causes & Control | Issue 12/2019

Abstract

Purpose

Racial disparity with shorter survival for Blacks than Whites is well known for many cancers. However, for brain cancer, some national cancer registry studies have shown better survival among Blacks compared to Whites. This study aimed to systematically investigate whether Blacks and Whites differ in survival and also in tumor characteristics and treatment for neuroepithelial brain tumors.

Methods

The National Cancer Institute’s Surveillance Epidemiology and End Results (SEER) database was used to identify non-Hispanic White and Black patients diagnosed with malignant, histologically confirmed neuroepithelial brain cancer from 2004 through 2015. Racial differences in brain cancer survival were compared using Kaplan–Meier curve and Cox proportional hazard models. The associations of race with tumor and treatment characteristics (location, size, grade, surgical type) were examined using multinomial logistic regression.

Results

After adjusting for demographic, tumor, and treatment factors, there were no significant differences in survival for non-Hispanic Blacks compared to non-Hispanic Whites [hazard ratio (HR) 1.05, 95% confidence interval (CI) 0.99–1.10]. Non-Hispanic Blacks had higher odds of being diagnosed with tumors of unknown grade [odds ratio (OR) 1.16, 95% CI 1.05–1.29], unknown size (OR 1.14, 95% CI 1.01–1.29), infratentorial (OR 1.12, 95% CI 1.01–1.24) or overlapping area (OR 1.39, 95% CI 1.14–1.70), and lower odds of having a total surgical resection (OR 0.83, 95% CI 0.74–0.93).

Conclusion

Non-Hispanic Blacks do not exhibit longer brain cancer-specific survival than non-Hispanic Whites. They were more likely to have tumors of unknown size or grade and less likely to receive total surgical resection, which may result from racial differences in access to and use of healthcare.

DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI, Jemal A (2016) Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin 66(4):290–308. https://doi.org/10.3322/caac.21340 CrossRefPubMed

DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A (2017) Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 67(6):439–448. https://doi.org/10.3322/caac.21412 CrossRefPubMed

Yoo W, Kim S, Huh WK, Dilley S, Coughlin SS, Partridge EE, Chung Y, Dicks V, Lee JK, Bae S (2017) Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States. PLoS ONE 12(2):e0172548. https://doi.org/10.1371/journal.pone.0172548 CrossRefPubMedPubMedCentral

Lin JJ, Mhango G, Wall MM, Lurslurchachai L, Bond KT, Nelson JE, Berman AR, Salazar-Schicchi J, Powell C, Keller SM, Halm EA, Leventhal H, Wisnivesky JP (2014) Cultural factors associated with racial disparities in lung cancer care. Ann Am Thorac Soc 11(4):489–495. https://doi.org/10.1513/AnnalsATS.201402-055OC CrossRefPubMedPubMedCentral

Benjamins MR, Hunt BR, Raleigh SM, Hirschtick JL, Hughes MM (2016) Racial disparities in prostate cancer mortality in the 50 largest US cities. Cancer Epidemiol 44:125–131. https://doi.org/10.1016/j.canep.2016.07.019 CrossRefPubMed

Robbins AS, Siegel RL, Jemal A (2012) Racial disparities in stage-specific colorectal cancer mortality rates from 1985 to 2008. J Clin Oncol 30(4):401–405. https://doi.org/10.1200/jco.2011.37.5527 CrossRefPubMed

Khawja SN, Mohammed S, Silberfein EJ, Musher BL, Fisher WE, Van Buren G II (2015) Pancreatic cancer disparities in African Americans. Pancreas 44(4):522–527. https://doi.org/10.1097/mpa.0000000000000323 CrossRefPubMed

Jinjuvadia R, Jinjuvadia K, Liangpunsakul S (2013) Racial disparities in gastrointestinal cancers-related mortality in the U.S. population. Dig Dis Sci 58(1), 236–243. DOI: 10.1007/s10620-012-2312-3.

Siegel RL, Miller KD (2016) Jemal A (2016) Cancer statistics. CA Cancer J Clin 66(1):7–30. https://doi.org/10.3322/caac.21332 CrossRef

10.

Deorah S, Lynch CF, Sibenaller ZA, Ryken TC (2006) Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus 20(4):E1. https://doi.org/10.3171/foc.2006.20.4.E1 CrossRefPubMed

11.

Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, Jemal A, Anderson RN, Ajani UA, Edwards BK (2011) Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 103(9):714–736. https://doi.org/10.1093/jnci/djr077 CrossRefPubMedPubMedCentral

12.

Barnholtz-Sloan JS, Sloan AE, Schwartz AG (2003) Racial differences in survival after diagnosis with primary malignant brain tumor. Cancer 98(3):603–609. https://doi.org/10.1002/cncr.11534 CrossRefPubMed

13.

Barnholtz-Sloan JS, Maldonado JL, Williams VL, Curry WT, Rodkey EA, Barker FG II, Sloan AE (2007) Racial/ethnic differences in survival among elderly patients with a primary glioblastoma. J Neurooncol 85(2):171–180. https://doi.org/10.1007/s11060-007-9405-4 CrossRefPubMed

14.

Pan IW, Ferguson SD, Lam S (2015) Patient and treatment factors associated with survival among adult glioblastoma patients: a USA population-based study from 2000–2010. J Clin Neurosci 22(10):1575–1581. https://doi.org/10.1016/j.jocn.2015.03.032 CrossRefPubMed

15.

Bohn A, Braley A, Rodriguez de la Vega P, Zevallos JC, Barengo NC (2018) The association between race and survival in glioblastoma patients in the US: A retrospective cohort study. PLoS ONE 13(6):e0198581. https://doi.org/10.1371/journal.pone.0198581 CrossRefPubMedPubMedCentral

16.

Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA (2015) Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA 313(2):165–173. https://doi.org/10.1001/jama.2014.17322 CrossRefPubMed

17.

Efird JT, Landrine H, Shiue KY, O'Neal WT, Podder T, Rosenman JG, Biswas T (2014) Race, insurance type, and stage of presentation among lung cancer patients. SpringerPlus 3:710. https://doi.org/10.1186/2193-1801-3-710 CrossRefPubMedPubMedCentral

18.

Sayegh ET, Aranda D, Kim JM, Oh T, Parsa AT, Oh MC (2014) Prognosis by tumor location in adults with intracranial ependymomas. J Clin Neurosci 21(12):2096–2101. https://doi.org/10.1016/j.jocn.2014.05.011 CrossRefPubMedPubMedCentral

19.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol 114(2):97–109. https://doi.org/10.1007/s00401-007-0243-4 CrossRefPubMedPubMedCentral

20.

Butowski NA (2015) Epidemiology and diagnosis of brain tumors. Continuum (Minneapolis, Minn) 21(2 Neuro-oncology):301–313. https://doi.org/10.1212/01.CON.0000464171.50638.fa CrossRef

21.

Claus EB, Black PM (2006) Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973–2001. Cancer 106(6):1358–1363. https://doi.org/10.1002/cncr.21733 CrossRefPubMed

22.

Silber JH, Rosenbaum PR, Clark AS, Giantonio BJ, Ross RN, Teng Y, Wang M, Niknam BA, Ludwig JM, Wang W, Even-Shoshan O, Fox KR (2013) Characteristics associated with differences in survival among black and white women with breast cancer. JAMA 310(4):389–397. https://doi.org/10.1001/jama.2013.8272 CrossRefPubMed

23.

National Cancer Institute Surveillance Epidemiology and End Result Program (2018) https://seer.cancer.gov/registries/. Accessed 29 June 2018

24.

Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2017) CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol 19(suppl_5):v1–v88. https://doi.org/10.1093/neuonc/nox158

25.

McCarthy BJ, Surawicz T, Bruner JM, Kruchko C, Davis F (2002) Consensus conference on brain tumor definition for registration. November 10, 2000. Neuro Oncol 4(2):134–145. https://doi.org/10.1093/neuonc/4.2.134 CrossRefPubMedPubMedCentral

26.

Chandana SR, Movva S, Arora M, Singh T (2008) Primary brain tumors in adults. Am Fam Physician 77(10):1423–1430PubMed

27.

SEER (2018) Topographic sites. https://training.seer.cancer.gov/brain/tumors/abstract-code-stage/topographic.html. Accessed 29 June 2018

28.

Nizamutdinov D, Stock EM, Dandashi JA, Vasquez EA, Mao Y, Dayawansa S, Zhang J, Wu E, Fonkem E, Huang JH (2018) Prognostication of survival outcomes in patients diagnosed with glioblastoma. World Neurosurg 109:e67–e74. https://doi.org/10.1016/j.wneu.2017.09.104 CrossRefPubMed

29.

Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL, Anderson RN, Henley SJ, Kohler BA, Penberthy L, Feuer EJ, Weir HK (2017) Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djx030 CrossRefPubMedPubMedCentral

30.

Gittleman H, Kromer C, Ostrom QT, Blanda R, Russell J, Kruchko C, Barnholtz-Sloan JS (2017) Is mortality due to primary malignant brain and other central nervous system tumors decreasing? J Neurooncol 133(2):265–275. https://doi.org/10.1007/s11060-017-2449-1 CrossRefPubMed

31.

Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS (2018) Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncol 4(9):1254–1262. https://doi.org/10.1001/jamaoncol.2018.1789 CrossRefPubMedPubMedCentral

32.

McGuire CS, Sainani KL, Fisher PG (2009) Both location and age predict survival in ependymoma: a SEER study. Pediatr Blood Cancer 52(1):65–69. https://doi.org/10.1002/pbc.21806 CrossRefPubMed

33.

Daniel CL, Gilreath K, Keyes D (2017) Colorectal cancer disparities beyond biology: Screening, treatment, access. Front Biosci (Landmark Ed) 22:465–478CrossRef

34.

Press R, Carrasquillo O, Sciacca RR, Giardina EG (2008) Racial/ethnic disparities in time to follow-up after an abnormal mammogram. J Womens Health (Larchmt) 17(6):923–930. https://doi.org/10.1089/jwh.2007.0402 CrossRef

35.

Coughlin SS, Blumenthal DS, Seay SJ, Smith SA (2016) Toward the elimination of colorectal cancer disparities among African Americans. J Racial Ethn Health Disparities 3(4):555–564. https://doi.org/10.1007/s40615-015-0174-z CrossRefPubMed

36.

Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G (2014) High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii93–101. 10.1093/annonc/mdu050

37.

Kiechle JE, Abouassaly R, Gross CP, Dong S, Cherullo EE, Zhu H, Trinh QD, Sun M, Meropol NJ, Hoimes CJ, Ialacci S, Kim SP (2016) Racial disparities in partial nephrectomy persist across hospital types: results from a population-based cohort. Urology 90:69–74. https://doi.org/10.1016/j.urology.2015.10.035 CrossRefPubMed

38.

Chen AY, Halpern MT, Schrag NM, Stewart A, Leitch M, Ward E (2008) Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998–2005). J Natl Cancer Inst 100(7):462–474. https://doi.org/10.1093/jnci/djn057 CrossRefPubMed

39.

Dehal A, Abbas A, Johna S (2013) Racial disparities in clinical presentation, surgical treatment and in-hospital outcomes of women with breast cancer: analysis of nationwide inpatient sample database. Breast Cancer Res Treat 139(2):561–569. https://doi.org/10.1007/s10549-013-2567-1 CrossRefPubMed

40.

Bristow RE, Zahurak ML, Ibeanu OA (2011) Racial disparities in ovarian cancer surgical care: a population-based analysis. Gynecol Oncol 121(2):364–368. https://doi.org/10.1016/j.ygyno.2010.12.347 CrossRefPubMed

41.

Iwamoto FM, Reiner AS, Panageas KS, Elkin EB, Abrey LE (2008) Patterns of care in elderly glioblastoma patients. Ann Neurol 64(6):628–634. https://doi.org/10.1002/ana.21521 CrossRefPubMed

42.

Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA (2010) Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 102(20):1584–1598. https://doi.org/10.1093/jnci/djq366 CrossRefPubMedPubMedCentral

43.

Utada M, Ohno Y, Shimizu S, Hori M, Soda M (2012) Comparison between overall, cause-specific, and relative survival rates based on data from a population-based cancer registry. Asian Pac J Cancer Prev 13(11):5681–5685CrossRef

44.

Sarfati D, Blakely T, Pearce N (2010) Measuring cancer survival in populations: relative survival vs cancer-specific survival. Int J Epidemiol 39(2):598–610. https://doi.org/10.1093/ije/dyp392 CrossRefPubMed

45.

Ening G, Osterheld F, Capper D, Schmieder K, Brenke C (2015) Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification. J Cancer Res Clin Oncol 141(6):1131–1137. https://doi.org/10.1007/s00432-014-1907-9 CrossRefPubMed

46.

Chambless LB, Parker SL, Hassam-Malani L, McGirt MJ, Thompson RC (2012) Type 2 diabetes mellitus and obesity are independent risk factors for poor outcome in patients with high-grade glioma. J Neurooncol 106(2):383–389. https://doi.org/10.1007/s11060-011-0676-4 CrossRefPubMed

Title: Racial differences in brain cancer characteristics and survival: an analysis of SEER data
Authors: Julie A. Bytnar
Jie Lin
Craig D. Shriver
Kangmin Zhu
Publication date: 01-12-2019
Publisher: Springer International Publishing
Keywords: Glioblastoma
Glioblastoma
Brain Tumor
Glioblastoma
Published in: Cancer Causes & Control / Issue 12/2019
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-019-01239-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2019

Disparities in surgery for early-stage cancer: the impact of refusal

Changing trends in liver cancer incidence by race/ethnicity and sex in the US: 1992–2016

Economics of public health programs for underserved populations: a review of economic analysis of the National Breast and Cervical Cancer Early Detection Program

Body size and dietary risk factors for aggressive prostate cancer: a case–control study

Polymorphisms in oxidative stress pathway genes and prostate cancer risk

Changes in use of opioid therapy after colon cancer diagnosis: a population-based study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer